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Abstract 
Measures of small and large artery dysfunction have not been investigated in a single cohort 
for the prediction of cardiovascular (CV) events in patients with non-dialysed (ND) chronic 
kidney disease (CKD). This prospective cohort study aimed to determine whether central 
pulse wave velocity (cPWV), central pulse pressure (CPP) or microvascular post-occlusive 
reactive hyperaemia area (PORHHA) independently predict CV events and mortality in CKD-
ND. 
Ninety-four stage 1-5 CKD-ND (65.3±13.1 year; eGFR 35.3(22.8-49.4) ml/min/1.73m2) 
patients were followed-up for a median of 52(36-65) months and had baseline cPWV, CPP 
measured by applanation tonometry, and PORHHA by Laser Doppler Flowmetry. Multiple 
failure time Cox-regression models were used to determine the predictive role of vascular 
parameters on CV mortality and events.  
Based on multiple linear regressions baseline age, diabetes, CV disease, and systolic blood 
pressure (SBP) were independently related to cPWV (R2=0.3), SBP and PORHHA to CPP 
(R2=0.45), while CPP was the only parameter independently related to PORHHA (R2=0.16, all 
p<0.05). During follow up 41 CV events occurred (14 CV deaths). In univariate analyses 
cPWV (1.07 (1.02-1.13) per m/s), CPP (1.04 (1.01-1.07) per mmHg), and lnPORHHA (0.70 
(0.58-0.85) per ln(mU*sec)) were all related to the outcome. Baseline diabetes (HR 3.07 
(1.65-5.68)), lnFGF23 (fibroblast growth factor 23; 1.86 (1.13-3.06) per RU/mL) and CPP 
(1.04 (1.01-1.07) per mmHg) were independent predictors of CV events. 
The impaired pulsatile component of large arteries (CPP) independently of other vascular 
markers (cPWV, PORHHA) predicted CV outcomes in CKD-ND. CPP may integrate the 
information provided by cPWV and PORHHA. 
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Summary Table 
 
The significance of micro- and macrovascular biomarkers on cardiovascular 
outcome in chronic kidney disease –A prospective cohort study 
What is known about topic 
– Non-dialysed chronic kidney disease (CKD-ND) is characterised by large and 
small vessel dysfunction, as assessed by central pulse wave velocity (cPWV), 
central pulse pressure, and post-occlusive reactive hyperaemia (PORHHA) 
– The role of these micro-and macrovascular markers in the prediction of 
cardiovascular (CV) outcome has not been previously evaluated in a single 
cohort of CKD-ND. 
What this study adds 
– Among cPWV, CPP and PORHHA, the impaired pulsatile component of central 
arteries (CPP) was the primary predictor of CV outcome. 
– CPP seems to integrate the information provided by cPWV and PORHHA. 
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Introduction 
The risk of cardiovascular (CV) events and all-cause mortality increases with worsening 
kidney function and it approaches a hundred-fold in end-stage renal disease (ESRD) 
compared to the general population [1]. Patients with chronic kidney disease (CKD) are more 
likely to die of CV disease before they get to ESRD that cannot be fully explained by 
decreased glomerular filtration (eGFR) and traditional risk factors. Thus CKD related 
vascular and metabolic alterations are suspected to explain the additional risk in this 
population. 
Renal anaemia, disturbances in mineral metabolism and systemic inflammation are 
known to be potential non-traditional CV risk factors [2,3,4] and serve as part of the 
pathophysiological background of accelerated athero- and arteriosclerosis of the large and 
small arteries in ESRD. Increased central pulse wave velocity (cPWV)  and central pulse 
pressure (CPP)  independently predict target organ damage, such as coronary artery disease 
(CAD), acute coronary syndrome (ACS), cerebrovascular diseases (stroke or transient 
ischemic attack - TIA), peripheral artery disease (PAD) at a subclinical stage in ESRD [5,6]. 
However, the role of these vascular biomarkers of subclinical organ damage and renal 
comorbid conditions as risk factors of CV events and death at earlier stages of CKD is 
uncertain [7]. In fact, the predictive values of increased CPP and cPWV in non-dialysed (ND) 
CKD have been less studied [8,9,10,11,12]. Furthermore, while there is plenty of evidence 
that detectable microvascular injury - as the other end of the spectrum of vascular dysfunction 
- begins at an early stage of CKD, it is not known whether this would also be predictive for 
CV events in CKD. Indeed, only one follow-up study [13] is available in which post-
occlusive reactive hyperaemia (PORH) measured by Laser Doppler Flowmetry (LDF) was 
associated with the development of CV diseases independent of Framingham and Cardiorisk 
cardiovascular risk scores. Furthermore, no previous study in CKD-ND considered the 
predictive roles of cPWV, CPP and PORH in a single cohort. 
The aim of our cohort study was therefore to assess the association of micro- and 
macrovascular biomarkers (cPWV, CPP, PORHHA) with traditional and non-traditional CV 
risk factors, and to evaluate their independent predictive value for CV events and mortality in 
“mild-to-severe” CKD-ND cases.  
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Methods 
 
This was a prospective cohort study of stage 1-5 CKD-ND patients with baseline 
clinical, biochemical, micro- and macrovascular measurements, and with CV events and 
mortality as outcome during follow-up.  
 
Patients  
Initially 108 hypertensive CKD-ND stage 1-5 individuals were enrolled with baseline 
clinical biochemical and vascular measurements, however only 103 agreed to participate. 
Convenience sampling was used with consecutive inclusion of CKD patients presenting at the 
two tertiary care outpatient clinics that were included to our study (Semmelweis University 
Ist. Department of Internal Medicine Semmelweis University and St Imre University 
Teaching Hospital, Budapest, Hungary). They were then followed for a median of 52 (36-65) 
months from 2007 to 2013. Further 9 people were excluded due to missing baseline or follow-
up data. Finally 94 patients were involved and followed-up. We compared baseline 
characteristics of participants and non-participants and found no major differences between 
these groups.  
None of the patients were hospitalised or had atrial fibrillation at the time of baseline 
investigations. No other specific inclusion or exclusion criteria were applied. 
Antihypertensive treatment was tailored according to the latest recommendations of the 
European Society of Hypertension for reaching target values [14]. 
Follow-up data were collected between April and July 2013 by telephone interviews 
with the patients, their general practitioners or treating physicians and the information 
gathered were in all cases verified by original chart review. Follow up was censored at the last 
occurrence of a documented CV event (ACS, heart failure requiring hospitalisation, stroke or 
TIA, PAD verified by angiography or need for an intervention) or death due to the above CV 
causes. Laboratory data and vascular biomarkers were not collected during follow-up.  
 
Power analysis 
Based on the observed difference of 7 mmHg central pulse pressure in the Strong Heart 
Study [15] between participants with and without incident cardiovascular events we expected 
a difference with similar magnitude in our population. After the enrolment of the first 25 
participants, we calculated the standard deviation of central pulse pressure on enrolled 
population (SD 12 mmHg). Furthermore, based on literature data from similar populations 
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with a median eGFR of 30-44 ml/min/1.73m2 we expected 11 cardiovascular events per 100 
person years of follow-up that translates to 44 events during the planned 4-year study. Taken 
together all these information we needed to enrol 93 participants to have an 80% power to 
detect a 7 mmHg difference in central pulse pressure between cases and non-cases with an 
alpha of 0.05. Our observation of a difference of 8 mmHg (47.1 ± 11.7 vs. 55.2± 13.8 mmHg, 
p=0.004) well corresponds to the power calculations. 
 
Macrovascular injury and blood pressure measurements 
Measurements of vascular markers for a given patient (cPWV and CPP or PORHHA) 
were performed in a random order after one another on the same morning at baseline.  
Subjects were asked to refrain from smoking on the day of the study and not to consume 
caffeine-containing drinks at least 4 hours before the start of the measurements, but to take 
their regular morning medication. Tests were carried out in a temperature-controlled room 
(24±1°C) with the subjects in supine position, after a 20 minute rest period [16]. 
cPWV was measured by applanation tonometry (PulsePen device; DiaTecne s.r.l. 
Milan, Italy) [17] in accordance with the recommendations at that time [16] by capturing 
sequential recordings of the arterial pressure wave at the carotid and femoral arteries, and by 
measurement of the distance between the carotid and the femoral sampling sites. Since 
arguments for the use of 80% of the direct carotid-femoral distance as the most accurate 
measurement were provided in the latest expert consensus document, our data were calculated 
accordingly [18]. cPWV was calculated by the PulsePen software as the ratio of the distance 
and the transit time of the pulse pressure wave along the aorta. Pulse wave amplitude was 
calibrated to brachial mean and diastolic pressures, measured immediately prior to each 
sequence of pulse wave capture at the two sites. Mean arterial pressure was calculated by the 
PulsePen software as diastolic pressure + 0.4 pulse pressure. Recordings with a systolic or 
diastolic variability of consecutive waveforms above 10% or with the amplitude of the pulse 
wave signal being less than 80 mV were discarded. All measurements were done in duplicates 
by J.N, J. E, and Zs.N. and their averages were used in the calculations.  
CPP was measured by the same device and calculated as the difference of the central 
systolic and diastolic blood pressure values recorded at the carotid sampling site. 
All brachial blood pressure measurements throughout the study were performed by the 
validated oscillometric BpTRU device (VSM Meditech, Vancouver, Canada) with four 
sequential measurements manually averaged.  
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Microvascular function test 
For Laser Doppler Flowmetry (LDF) measurements, blood pressure and heart rate of the 
subjects were determined as above. Laser Doppler instrument (Periflux 5001, Stockholm, 
Sweden, wavelength 780 mm) was used during the study as described previously [19]. In 
short, during the PORHHA test after the registration of the baseline flow for 60 seconds on the 
volar surface of the left forearm 10 cm below the elbow with a standard LDF probe, brachial 
arterial occlusion was applied with 40 mmHg suprasystolic pressure by a pneumatic cuff of a 
sphygmomanometer for 3 minutes to reach the biological zero. After the release of the 
pressure, perfusion (measured as perfusion unit (PU)) rise high and rapidly above the pre-
ischemic PU values.  The software analysed the data automatically and calculated several 
indices such as the initial baseline value, slope value, peak flow, percent change in perfusion 
from baseline to maximum values, time to reach the maximum hyperaemia, time to reach the 
half value after the maximum hyperaemia, and the area of hyperaemia. This latter 
measurement (abbreviated as: PORHHA, unit: PU*sec – perfusion unit * second) seems to be 
the most accurate parameter to assess the hyperaemic response, as it includes three variables 
(speed, intensity, and duration) and this was used in the analyses as representative of the 
microvascular function [20, 21]. In their study, Stiefel P et al found a „cut-off” PORHHA of 
865 PU*sec to have an 82% sensitivity and a 97% specificity to distinguish microvascular 
dysfunction of coronary artery disease patients from healthy controls [20]. 
According to previous measurements in our laboratory, the day to day variability of this 
system was 16-21%, which is comparable to other studies [21]. All PORHHA measurements 
were performed by J.E. and analysed by J.N. 
 
Epidemiologic and Laboratory data 
Baseline data on smoking habits (current), diabetes (DM, any type), hypertension, 
coronary artery disease (previous acute myocardial infarction or coronary intervention), 
chronic heart failure (previous diagnosis), Peripheral Artery Disease (PAD; documented by 
angiography or intervention) and cerebrovascular disease (previous stroke or TIA) were 
collected by health record review. The Charlson Comorbidity Index was used for overall 
characterization of co-morbidity of the studied population [22,23].  
Data on haemoglobin (Hgb), serum calcium (Ca), phosphate (iP), albumin (Alb), 
parathormon (iPTH), creatinine, C-reactive protein (CRP), serum cholesterol (Chol), 
triglyceride (Tg), and LDL-cholesterol were evaluated at baseline. Routine blood chemistry 
measurements were performed by a Hitachi auto analyser.  Intact parathyroid hormone 1-84 
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(iPTH) was determined by immune-chemiluminomtric two-site assay (CIBA-CORNING, 
Frenwald, Germany). Baseline eGFR was calculated using the four-variable Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation [5]. Circulating concentration of 
fibroblast growth factor 23 (FGF23) was measured using a second-generation C-terminal 
ELISA (Immutopics, San Clemente, CA). Albuminuria was characterised by albumin-
creatinine ratio (ACR) measured from first morning spot urine according to KDIGO 
recommendations [5]. 
 
Statistical analysis 
 All data analysis was performed by STATA (StataCorp Lp. Texas USA) and Statistica 
version 11.0 (StatSoft Inc. Tulsa USA). Data are given as mean and standard deviation, unless 
indicated otherwise. Values are presented as median and interquartile range when data did not 
display a normal distribution and they were transformed logarithmically for further analyses. 
In the group analysis of anthropometric and clinical parameters, Student’s t-test for 
independent samples or Mann Whitney U test was used as appropriate.  
108 people were invited to participate; however only 103 agreed it and a further 9 
people were excluded due to missing baseline or follow-up data. We compared baseline 
characteristics of participants and non-participants and found no major differences between 
these groups. As the number of participants with missing data was relatively low, we used 
complete-case analysis. No multiple imputations were performed due to the limited sample 
size.  
In the baseline cross sectional analyses univariate and multivariate (stepwise, ridge) 
linear regressions were performed to determine the main associations of the macro- and 
microvascular parameters (cPWV, CPP, PORHHA). The predictor variables considered were 
the ones listed in table 1. The variables that showed a significant association with the given 
dependent variable in univariate models were considered in the final multivariate model. 
(Table 2).  
To assess the predictive values of cPWV, CPP and PORHHA for CV events and CV 
mortality, multiple failure times Cox proportional hazard regression analyses were used with 
conditional risk set modelling. This method accommodates for the fact that one patient may 
have more than one outcome event. We first performed univariate analyses considering 
variables listed in table 1. Confounding was addressed in multiple linear and multivariate 
Cox-regression models with adjustment for potential clinical predictors. Final models were 
11 
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selected using backward elimination to reach the most parsimonious models. (Table 3 and 
Online Data Supplement Table 1.)  
Finally, to determine the sensitivity of our data we repeated the analyses with the more 
usual method of censoring patients at the first occurrence of a CV event (a total of 31 events). 
Our main finding, i.e. CPP is the only vascular marker that significantly and independently 
predicts outcome has not been altered by this analysis. (Online Data Supplement Table 2.) 
A “p” value with a two-sided alpha of 0.05 was considered statistically significant. 
Hazard ratios are presented with their corresponding 95% confidence interval. 
 
Ethics  
CKD-ND patients in stages 1-5, who gave written, informed consent for participation, 
were included. The study protocol was approved by the Local Ethical Committee of the two 
investigation sites and it was in accordance with the principles of the Declaration of Helsinki. 
 
 
Results 
Descriptive statistical analysis at baseline 
Table 1 displays baseline characteristics, concomitant diseases, traditional and non-
traditional risk factors, metabolic and vascular parameters of our patients and divided into two 
subgroups by eGFR less than, or equal to and higher than 30 ml/min/1.73 m2. 
The causes of kidney disease were heterogeneous (number of cases in parentheses): 
glomerulonephritis (14), diabetic nephropathy (27), hypertensive nephrosclerosis (14), 
chronic tubulointerstitial nephritis (17), vascular cause (4), polycystic kidney disease (7), 
tumor (1) and unknown (10). There were two normotensive subjects with CKD with 
polycystic kidney disease and glomerulonephritis.  
All but one patient received antihypertensive medication: (case numbers in parentheses) 
ACE inhibitors (84), calcium channel blockers (48), diuretics (68),  ß-receptor blockers (52), 
α-receptor blockers (15), long-acting nitrate (14) and centrally-acting antihypertensive drugs 
(13), either alone or in combination. Acetylsalicylate platelet aggregation inhibitor was taken 
by 36 patients, while 15 individuals took clopidogrel. Thirty five patients   required 
erythropoietin, 34 received active vitamin-D, and 8 needed calcium carbonate phosphate 
binder therapy. 
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As expected, the group with an eGFR below 30 ml/min/1.73 m2 had a worse metabolic 
status as indicated by their elevated iP, iPTH, FGF23, CRP, ACR and lower haemoglobin 
values.  
Baseline cPWV, CPP, and PORHHA values were 12.5±4.5m/s, 52±13mmHg, 593 
PU*sec (280-1046), respectively, with no significant differences between the less and more 
advanced CKD groups.  
At baseline there were no differences between the parameters of micro- and 
macrovascular damage according to the use of any antihypertensive, platelet aggregation 
inhibitor, erythropoietin or active vitamin-D therapy. Nearly half of our population had DM at 
baseline. The diabetic group had significantly higher cPWV (14.2±4.4 vs. 11.3±4.2 p=0.002), 
lower PORHHA (421 (158-999) vs. 696 (386-1139) p=0.03), but CPP was not significantly 
different between the groups (54±13 vs. 50±12 p=0.08).  
 
Cross sectional analysis at baseline 
Baseline associations of the vascular biomarkers (i.e. cPWV, CPP, lnPORHHA) with 
other baseline clinical and biochemical parameters, as assessed by uni- and multivariate linear 
regressions are displayed in table 2. Age, diabetes, previous CV disease, and systolic blood 
pressure (SBP) were related to cPWV (R2=0.3). CPP was associated with SBP and PORHHA 
(R2=0.45). CPP was the only parameter significantly related to PORHHA (R2=0.16) in the 
multivariate model. 
 
Prospective data analysis 
During a median of 52 (36-65) months of observation time no patients were lost to 
follow-up. In 31 participants, 41 CV events were recorded and used in the analyses. It 
represents an incidence rate of 9.8 events per 100 patient years. The distribution of the 
primary events: Fourteen patients died of CV causes (acute coronary syndrome 4, stroke 2, 
heart failure 7, and peripheral artery disease 1), and there were 27 additional CV events (acute 
coronary syndrome 4, stroke 6, heart failure 11, peripheral artery disease 6). 10 patients had a 
second CV event, including 7 CV deaths. All 41 primary and secondary events were used as 
hard end points in the multiple failure time Cox regression analysis.  
In univariate Cox regression analyses all three studied vascular parameters were 
significantly associated with the outcome, hazard ratios for cPWV were 1.07 (1.02-1.13), for 
CPP 1.04 (1.01-1.07), and for PORHHA 0.70 (0.58-0.85), respectively. 
13 
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As a result of the multivariate backward Cox regression model building, that included 
the other significant univariate predictors besides the three studied vascular parameters, only 
the presence of DM (3.06 (1.65-5.67)), lnFGF23 (1.86 (1.13-3.06)) and CPP (1.04 (1.01-
1.07)) remained independent predictors of CV mortality and events (Table 3 and online data 
supplement Table 1) while cPWV and lnPORHHA have lost their significant predictive value 
for CV events. 
To determine the sensitivity of our data we repeated all these analyses with censoring 
patients at the first occurrence of a CV event (a total of 31 events). In this analysis again CPP 
remained the only significant vascular predictor of the outcome while cPWV as well as 
lnPORHHA lost their initial univariate significance in predicting CV outcome. (Online data 
supplement Table 2.) 
 
Discussion 
 
The predictive role of macro- and microvascular biomarkers (cPWV, CPP, PORHHA) on 
CV outcome in CKD-ND was investigated in our prospective cohort study, an analysis that 
has never been previously performed in a single cohort. Our main findings demonstrate that 
while there is an association between the markers of micro- and macrovascular injury and CV 
outcome, CPP seems to be the one that may best determine CV morbidity and mortality. 
Additionally, the presence of diabetes and higher FGF23, an early marker of disturbed 
mineral metabolism and vascular calcification were also found to be independent predictors of 
CV outcome in CKD-ND. 
Our population can be classified as high-risk for CV diseases, as they had an event rate 
of 9.8 per 100 patient years during follow up. This cannot be explained solely by the presence 
of Framingham risk factors [24]. Indeed, the measured cPWV (12.5±4.5m/s) and CPP 
(52±13mmHg) values of our patients exceeded the „cut-off” values (PWV >10 m/sec and 
CPP >50 mmHg, respectively) recommended by the ESH guideline and the Strong Heart 
Study [17,25] may in part explain this higher event rate.  Our patients with an eGFR of less 
than 30 ml/min/1.73 m2 tended to have more baseline CV diseases, such as coronary, 
cerebrovascular and peripheral artery disease, which likely further increased their risk of 
future CV events. Thus, among our patients with worsening kidney function, an increased 
number of comorbidities could explain the rate of events that exceeds the 3 events per 100 
patient year reported by Baumann et al. [11] and the 5.13 events per 100 patient year in Hoorn 
study [26]. While in the last decade cPWV has been proven to be an independent risk factor 
14 
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of CV risk in the general and ESRD population [2,3,27] only a limited number of studies had 
been performed with this vascular parameter in CKD-ND. In fact, only the above two 
prospective cohort studies investigated cPWV in a CKD-ND population. In the first study 
cPWV was found to predict all-cause mortality, while in the latter study cPWV was related to 
cardiovascular events after 7.6 years of follow-up [11,26]. Other recent studies demonstrated 
that decreased arterial elasticity is related to CKD progression; long-term CV outcomes have 
not been reported. [28,29] There is one additional prospective cohort study by Quiroga et al 
[12], who found male gender, diabetes, kidney disease progression and baseline CV disease to 
be predictors of all-cause mortality in their Spanish cohort. It is important to note, however, 
that central arterial elasticity parameters, such as CPP were not examined in their study. As 
for the role of CPP in CKD-ND, only the cross sectional CRIC study examined and found 
CPP as being superior over peripheral pulse pressure to quantify the risk of CV disease and 
eGFR impairment [9].  
Microvascular injury measured by LDF has not been extensively studied prospectively; 
Rossi et al. [30] in their cross sectional analysis found PORHHA values being an incremental 
determinant of atherosclerosis besides brachial ankle index in type 1 diabetes. The only 
prospective study performed among ESRD patients concluded that PORHHA was a 
determinant of coronary artery disease and all-cause mortality [13].  
Our work is unique in that it is the first prospective study to investigate the combined 
effects of micro- and macrovascular markers, their relation to each other, and their 
independent effects on hard CV end points in a single cohort of CKD-ND patients, never 
previously performed in this population.  
Our cross sectional analysis suggests that CPP might represent an early functional sign 
of vascular injury, to which none of the metabolic markers (e.g. eGFR, anaemia, disturbed 
mineral metabolism) of CKD were related. We hypothesize that early stages of athero- and 
arteriosclerosis could lead to microstructural deterioration of central and peripheral arteries 
that lead to early hemodynamic dysfunction in the CKD environment. Early dysfunction of 
large conduit arteries (characterized by increased cPWV) may have a backward effect leading 
to left ventricular hypertrophy and also increase CPP. At the same time early small vessel 
dysfunction (characterised by decreased PORH) may increase wave reflections, contributing 
to the high pulsatile component of the aortic pressure (CPP) that directly damages target 
organs such as the heart, brain and kidneys [31]. Given the above physiological evidence, it 
seems reasonable to hypothesize that increased CPP could be an integrative marker of 
preclinical early target organ damage indicating both micro- and macrovascular injury [32]. 
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 Beyond CKD, traditional risk factors, such as diabetes also lead to a significantly worse 
metabolic state, hence accelerated athero- and arteriosclerosis. Thus small and large arterial 
injuries due to these risk factors might develop simultaneously which can be extensively 
described by CPP as an integrative marker of CV outcome in CKD-ND. While the presence 
of diabetes was expected to determine the outcome [33], in our study, it was also 
independently associated with CPP, rather than cPWV suggesting that CPP better described 
the clinically relevant vascular changes that occur in CKD. An explanation as for why 
PORHHA was not an independent predictor of outcome could be that the target organ damage 
characterized by increased CPP can be considered a more robust factor than a sole 
microvascular injury or structural central arterial stiffness marker itself. In summary, our 
prospective data seem to support the notion that increased CPP is indeed an early integrative 
marker of large and small vessel injury, with clinically relevant consequences in CKD-ND. 
The plasma level of the new early biomarker of deranged mineral metabolism and 
vascular calcification, FGF23, rises already at initial stages of CKD and it has been shown to 
relate to several target organ damages leading to cardiovascular death i.e. arterial stiffness or 
endothelial dysfunction. Our study confirms the role of FGF23 as an independent predictor of 
CV death and events as summarised recently by Xiao Y. et al. in their meta-analysis [34].  
In conclusion, the impaired pulsatile component of the central arteries characterized by 
increased CPP, as an integrative marker of micro- and macrovascular dysfunction proved to 
be the sole, independent and robust vascular predictor of CV outcome in our CKD-ND 
population. CPP seems to integrate the information provided by cPWV and PORHHA. 
Additionally, the presence of diabetes deserves special attention considering its continued 
predictive role for higher rate of CV events.  FGF23 may also indicate increased CV risk and 
offer a potential future screening tool in risk stratification methods. Whether CPP can 
specifically be influenced by targeted vascular or metabolic therapy to alter small and large 
vascular function and whether all of that would have an impact on long-term CV outcome are 
to be seen in future diagnostic and therapeutic trials.   
 
 
Limitations 
 
There are several limitations of our study to be acknowledged. While unique in its 
objectives, our study evaluated only a relatively small number of cases, that makes it difficult 
to homogenise the cohort, smooth the variation of group composition in each CKD stages, 
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and generalize our conclusions. Furthermore, as we had small patient numbers our confidence 
intervals are rather wide, and we hope that other ongoing cohort studies will support our 
findings on the fundamental role of CPP as an integrative marker of CV risk in this 
hypertensive CKD ND population. It is important to note that beside diabetes and FGF23, 
only CPP was predictive for the outcome, suggesting its robustness despite the small patient 
numbers. Nonetheless, further studies are needed to confirm the reliability of CPP as a clinical 
marker of CV risk stratification. We acknowledge that this was a sample of patients of two 
tertiary care nephrology clinics, and therefore selection bias that may limit generalizability 
(i.e. high baseline CV disease risk burden of our patients) cannot be ruled out. We realize that 
the method we used to assess microvascular reactivity with LDF and PORHHA is not entirely 
established. We, therefore, are awaiting the results of further studies with this method [35].  
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Table 1. Baseline data of the participants
n (%)
Males (%)
Smoke (current) (%)
Diabetes mellitus (%)
Cardiovascular disease (%)
Mean SD Mean SD Mean SD
 65.3  13.1  64.1  14.6  67.1  10.6
 28.16  4.83 28  4.29  28.39  5.58
4 (1-6) 3 (1-5) 5 (2-7)
 35.3 (22.8-49.4)  44.9 (37.7-55.3)  21.9 (15.5-26.3)
126 14 130 14 122 12
 4.89  1.1  4.88  1.03  4.91  1.21
 2.15  1.3  2.19  1.44  2.09  1.07
 2.55  0.82  2.57  0.85  2.51  0.8
 2.36  0.12  2.37  0.1  2.35  0.15
 1.22  0.24  1.15  0.2  1.33  0.25
 29.2 (20.9-55.3)  23.63 (19.3-34.8)  47.5 (28.3-80.5)
56 (38-104) 48 (28-65) 100 (50-180)
 45.3  4.2  45.4  4.4  45.1  4.0
 2.2 (0.9-4)  1.6 (0.6-3.1)  3.1 (1.1-6)
 8.43 (1.84-58.71)  5.02 (0.98-31.29)  20.49 (4.89-97.71)
135 16 135 15 134 17
73 10 74 9 72 11
67 12 65 10 69 14
 12.52  4.47  12.58  4.69  12.43  4.22
52 13 52 13 52 12
593 (280-1046) 523 (248-1007) 846 (370-1116)
* Data with non-normal distribution are given as median and interquartile range.
# p< 0.05 difference between groups of eGFR <and ≥ 30 ml/min/1.73 m2
No missing data. 
eGfr 
≥ 30ml/min/1.73 
m2
eGfr 
< 30ml/min/1.73 m2
45 (48) 32 (57) 13 (34)
All 
CKD patients
94 56 38
9 (10) 4 (7) 5 (13)
41 (44) 23 (41) 18 (47)
61 (65) 33 (59) 28 (74)
Coronary artery disease (%) 13 (14) 5 (9) 8 (21)
BMI (kg/m2)
Chronic heart failure (%) 18 (19) 8 (14) 10 (26 )
Cerebrovascular disease (%) 23 (24) 9 (16) 14 (37)
Peripheral artery disease (%) 50 (53) 28 (50) 22 (58)
Age (years)
CRP (mg/L) * #
CCI* #
eGFR (ml/min/1.73m2) * #
Hgb (g/L) #
Chol (mmol/L)
Tg (mmol/L)
LDL (mmol/L)
Ca (mmol/L)
iP (mmol/L) #
FGF23 (RU/mL) * #
iPTH (pg/mL) * #
Alb (g/L)
Abbreviations: n -case number, SD - standard deviation, CCI - Charlson Comorbidity Index, 
BMI - body mass index, eGFR - estimated glomerular filtration rate (EPI), 
Hgb - hemoglobin, Chol-cholesterol, Tg - triglyreride, LDL – low density lipoprotein, 
Ca - serum calcium,iP – serum inorganic phosphate, 
ACR - albumin creatinin ratio, SBP - peripheral systolic 
blood pressure, DBP - peripheral diastolic blood pressure, HR - heart rate, 
cPWV - central pulse wave velocity, CPP - central pulse pressure, 
PORHHA - post occlusive reactive hyperaemia area, PU-perfusion unit
PORHHA (PU*sec)*
ACR (mg/mmol) * #
SBP (mmHg)
DBP (mmHg)
HR (1/min)
cPWV (m/s)
CPP (mmHg)
Cardiovascular disease is defined as a documented baseline history of coronary artery disease, 
chronic heart failure, cerebrovascular or peripheral vascular disease.

Univariate models
ß r2 p ß r2 p ß r2 p
Age (years) 0.38 0.15 <0.001 0.11 0.01 0.31 0.16 0.03 0.12
CVD 0.45 0.21 <0.001 0.18 0.03 0.09 -0.04 0.00 0.68
DM 0.32 0.10 0.002 0.18 0.03 0.08 -0.25 0.06 0.02
BMI (kg/m2) -0.11 0.01 0.3 0.14 0.02 0.18 -0.08 0.01 0.47
ln eGFR -0.18 0.01 0.3 -0.12 0.01 0.38 0.03 0.00 0.88
Hgb (g/L) -0.14 0.02 0.19 -0.1 0.01 0.33 0.08 0.01 0.45
Chol (mmol/L) -0.01 0.00 0.89 0.1 0.01 0.36 -0.07 0.00 0.52
Tg (mmol/L) -0.15 0.02 0.15 0.02 0.00 0.84 -0.003 0.00 0.97
LDL (mmol/L) 0.11 0.01 0.32 0.14 0.02 0.19 -0.04 0.00 0.73
Ca (mmol/L) -0.14 0.02 0.19 -0.01 0.00 0.96 -0.17 0.03 0.11
iP (mmol/L) -0.12 0.02 0.24 0.07 0.00 0.52 -0.08 0.01 0.46
ln FGF23 -0.001 0.00 0.99 0.03 0.00 0.78 0.006 0.00 0.95
ln iPTH 0.14 0.02 0.19 0.04 0.00 0.69 0.15 0.02 0.16
Alb (g/L) -0.09 0.01 0.39 0.02 0.00 0.86 -0.06 0.00 0.6
ln CRP -0.03 0.00 0.59 -0.16 0.01 0.39 0.08 0.01 0.3
ln ACR 0.02 0.00 0.83 0.07 0.00 0.51 -0.15 0.02 0.15
SBP (mmHg) 0.32 0.10 0.002 0.65 0.42 <0.001 -0.21 0.05 0.04
DBP (mmHg) 0.01 0.00 0.93 0.19 0.04 0.07 0.14 0.02 0.19
HR (1/min) 0.07 0.00 0.52 -0.13 0.02 0.24 -0.09 0.01 0.42
cPWV (m/s) 1 0.29 0.09 0.005 -0.15 0.02 0.15
CPP (mmHg) 0.29 0.09 0.005 1 -0.41 0.17 <0.001
ln PORHHA -0.15 0.02 0.15 -0.41 0.17 <0.001 1
Multivariate models
ß SE p ß SE p ß SE p
Age (years) 0.25 0.096 0.01
CVD 0.22 0.099 0.03
DM 0.19 0.089 0.04 -0.17 0.093 0.07
CPP (mmHg) 0.03 0.106 0.77 -0.37 0.115 0.002
SBP (mmHg) 0.25 0.105 0.02 0.51 0.079 <0.001 0.04 0.114 0.76
cPWV (m/s) 0.08 0.079 0.29
ln PORHHA -0.27 0.077 0.001
Adj.R2 SEE p Adj.R2 SEE p Adj.R2 SEE p
0.30 3.739 <0.001 0.44 9.416 <0.001 0.16 1.048 <0.001
NA NA
NA NA
Table 2. Baseline associations of the vascular biomarkers 
– Uni- and multivariate linear regression models
NA
c PWV (m/s) CPP (mmHg) lnPORHHA
cPWV (m/s) CPP (mmHg) ln PORHHA
NA NA
NA NA
NA
Abbreviations: NA-not analysed, ß –regression  coefficient, p-level of significance, 
SE - standard error of ß, SEE - standard error of estimate, BMI - body mass index, 
ln - natural based logarithm, DM - diabetes mellitus, CVD - cardiovascular disease 
(coronary artery disease+chronic heart failure+peripheral artery disease+cerebrovascular 
disease), eGFR - estimated glomerular filtration rate, Hgb - hemoglobin, Chol-cholesterol, 
Tg - triglyreride, LDL – low density lipoprotein, Ca - serum calcium, 
iP – serum inorganic phosphate, ACR - albumin creatinin ratio, 
SBP - peripheral systolic blood pressure, DBP - peripheral diastolic blood pressure, 
HR - heart rate, cPWV - central pulse wave velocity, CPP - central pulse pressure, 
PORHHA - post occlusive reactive hyperaemia area


Univariate model 
Hazard 
Ratio P
Age (years) 1.01 0.99 1.04 0.2
Gender (male) 0.88 0.48 1.63 0.69
Smoking 0.84 0.31 2.31 0.74
DM 3.24  1.7 6.1 0.0001
CVD 2.65  1.11 6.34 0.03
BMI (kg/m2) 1.06 0.99 1.12 0.06
CCI 1.26 1.11 1.44 0.0001
ln eGFR 0.41 0.23 0.73 0.003
Hgb (g/L) 0.98 0.97 1.01 0.19
Chol (mmol/L) 0.88 0.72 1.08 0.23
Tg (mmol/L) 0.98 0.81 1.18 0.87
LDL (mmol/L) 0.94 0.69 1.27 0.69
Ca (mmol/L) 1.91 0.1 35.21 0.66
iP (mmol/L) 1.37 0.42 4.42 0.6
Alb (g/L) 1.03 0.94 1.11 0.5
ln CRP 1.31 0.80 2.16 0.28
ln FGF23 1.75 1.1 2.77 0.02
ln iPTH 1.31 0.90 1.89 0.16
ln ACR 1.04 0.89 1.21 0.64
SBP (mmHg) 1.02 1 1.04 0.12
DBP (mmHg) 0.99 0.96 1.03 0.97
HR (1/min) 1.02 1 1.04 0.13
cPWV (m/s) 1.07 1.02 1.13 0.004
CPP (mmHg) 1.04 1.01 1.07 0.005
ln PORH HA 0.7 0.58 0.85 0.0001
Final multivariate model
Hazard 
Ratio P=
DM 3.06 1.65 5.67 0.0001
ln FGF23 1.86 1.13 3.06 0.01
CPP (mmHg) 1.04 1.01 1.07 0.005
 95% confidence interval
CI 95%
Table 3. Uni- and multivariate multiple failure time 
Cox-proportional hazards regression analysis of cardiovascular 
morbidity and mortality risk predictors 
Abbreviations: CI - confidence interval, BMI - body mass index, ln - natural based logarithm, CCI - 
Charlson comorbidity index, DM - diabetes mellitus, CVD - cardiovascular disease (coronary 
artery disease+chronic heart failure+peripheral artery disease+cerebrovascular disease) , eGFR - 
estimated glomerular filtration rate (EPI), Hgb - hemoglobin, Chol-cholesterol, Tg - triglyreride, 
LDL – low density lipoprotein,  Ca - serum calcium, iP - serum inorganic phosphate, ACR - 
albumin creatinin ratio, SBP - peripheral systolic blood pressure, DBP - peripheral diastolic blood 
pressure, HR - heart rate, cPWV - central pulse wave velocity, CPP - central pulse pressure, 
PORHHA - post occlusive reactive hyperaemia area 
